Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eidos Therapeutics Inc (EIDX)

Eidos Therapeutics Inc (EIDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,159,452
  • Shares Outstanding, K 37,497
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,290 K
  • 60-Month Beta -0.94
  • Price/Sales 75.80
  • Price/Cash Flow N/A
  • Price/Book 10.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.55
  • Number of Estimates 4
  • High Estimate -0.50
  • Low Estimate -0.58
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -103.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.85 +55.20%
on 10/21/19
58.84 -5.44%
on 11/19/19
+19.35 (+53.32%)
since 10/18/19
3-Month
33.34 +66.89%
on 10/01/19
58.84 -5.44%
on 11/19/19
+10.64 (+23.64%)
since 08/20/19
52-Week
11.15 +399.01%
on 01/29/19
58.84 -5.44%
on 11/19/19
+41.43 (+291.56%)
since 11/20/18

Most Recent Stories

More News
Eidos Therapeutics, Inc. (EIDX) Moves to Buy: Rationale Behind the Upgrade

Eidos Therapeutics, Inc. (EIDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

EIDX : 55.64 (-3.39%)
CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation

BBIO : 33.29 (+9.90%)
EIDX : 55.64 (-3.39%)
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation

BBIO : 33.29 (+9.90%)
EIDX : 55.64 (-3.39%)
Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update

Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial results for the third quarter ended September 30, 2019 and...

EIDX : 55.64 (-3.39%)
BBIO : 33.29 (+9.90%)
BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed...

BBIO : 33.29 (+9.90%)
EIDX : 55.64 (-3.39%)
Alexion (ALXN) Collaborates With Stealth BioTherapeutics

Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

AMGN : 225.51 (+0.45%)
ALXN : 108.53 (-1.92%)
EIDX : 55.64 (-3.39%)
MITO : 7.72 (+3.28%)
Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced...

EIDX : 55.64 (-3.39%)
Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3 at 3:00 p.m. EDT in New York, NY.

EIDX : 55.64 (-3.39%)
Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019

Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.

BIIB : 285.40 (-0.01%)
ALXN : 108.53 (-1.92%)
AMGN : 225.51 (+0.45%)
EIDX : 55.64 (-3.39%)
EIDOS THERAPEUTICS (EIDX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Eidos Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations and breach of fiduciary duty claims...

EIDX : 55.64 (-3.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade EIDX with:

Business Summary

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.

See More

Key Turning Points

2nd Resistance Point 60.17
1st Resistance Point 57.91
Last Price 55.64
1st Support Level 53.42
2nd Support Level 51.19

See More

52-Week High 58.84
Last Price 55.64
Fibonacci 61.8% 40.62
Fibonacci 50% 34.99
Fibonacci 38.2% 29.37
52-Week Low 11.15

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar